MAPT and Alzheimer disease: Based on this previous literature, we designed a multisite biomarker study including three cohorts to test the hypothesis that the presence of astrocyte reactivity biomarker abnormality is a key element in determining the association of Aβ burden with early tau phosphorylation and aggregation biomarkers in preclinical AD.